ENANTA PHARMACEUTICALS INC (ENTA) Stock News

USA - NASDAQ:ENTA - US29251M1062 - Common Stock

10.4205 USD

-0.5 (-4.57%)

Last: 11/6/2025, 11:48:29 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ENTA Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

17 days ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

21 days ago - By: Benzinga - Mentions: ACHV GNPX KZR FEMY ...

12 Health Care Stocks Moving In Thursday's After-Market Session

2 months ago - By: Benzinga

4 Analysts Have This To Say About Enanta Pharma

a month ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

a month ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

a month ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

a month ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock

a month ago - By: Stocktwits - Mentions: IWV ITOT

Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update

a month ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

a month ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

2 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.

3 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Participate in September Investor Conferences

3 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

3 months ago - By: Zacks Investment Research - Mentions: FATE

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

3 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

3 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

4 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series

5 months ago - By: Yahoo Finance - Mentions: ABBV F TSLA BIP ...

AbbVie Secures FDA Approval to Expand Mavyret’s Label

5 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

5 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

6 months ago - By: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

6 months ago - By: Yahoo Finance - Mentions: AMAT WMT ADCT ARCT ...

AMAT Earnings: Demand Holding Up So Far